Important note

This AI stock analysis for Eli Lilly and Company is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Eli Lilly and Company - AI Stock Analysis

Analysis generated June 17, 2025

Eli Lilly and Company is a renowned pharmaceutical manufacturer with a long-standing history in the development of innovative medications. Since its inception in 1876, the company has grown to become a global leader in pharmaceutical innovation, focusing on areas such as oncology, immunology, neuroscience, endocrinology, and cardiovascular disease. Eli Lilly's commitment to research and development drives its diverse product portfolio and its position within the healthcare industry.

Fundamental Analysis

Revenue: For the last quarter, Eli Lilly reported revenue of $12.7B. This reflects a decrease of 5.94% compared to the previous quarter, signaling a potential concern in short-term revenue generation. However, on a year-over-year basis, revenue increased by 45.17%, demonstrating strong growth and successful product outputs over the past 12 months.

Net Income: Eli Lilly's net income for the last quarter was $2.76B. Similar to the revenue figures, this represents a decrease of 37.43% from the previous quarter, suggesting challenges in maintaining profitability. Nevertheless, on an annual comparison, net income has grown by 23.02%, indicating a healthy bottom line over a longer duration.

EBITDA: The EBITDA for the last quarter stood at $5.3B. This marks a decrease of 13.78% from the previous quarter, highlighting some operational setbacks. However, the year-over-year increase of 70.13% signifies robust operational efficiency and a significant improvement in earnings before interest, taxes, depreciation, and amortization.

P/E Ratio: The current Price-to-Earnings (P/E) ratio is 65.76. This high P/E ratio can indicate potential overvaluation and a bearish outlook among investors as the market price of the stock appears significantly higher relative to the company's earnings.

Technical Analysis

Current Stock Price: Today’s stock price for Eli Lilly is $793.29. This is an increase of 4.74% compared to a month ago, indicating a positive short-term trend. However, compared to a year ago, there is a decrease of 10.40%, which introduces concerns about the stock’s long-term performance.

Simple Moving Average (SMA10): The current 10-day Simple Moving Average (SMA10) is $803.04, higher than the previous SMA10 of $800.70. This uptrend suggests a potential rise in price movement, which could attract more investors in the short term.

Relative Strength Index (RSI): The RSI stands at 62.8, indicating a neutral condition. An RSI within this range does not suggest any immediate overbought or oversold pressures but indicates that investors should watch closely for any emerging trends.

Alternative Data Analysis

Job Postings and Employee Sentiment: Eli Lilly and Company has approximately 1,000 open positions, which is down by 6% over the last couple of months. This reduction might reflect efforts to improve margins or cut costs, which is not usually a positive sign for a growing company. However, around 85% of employees have a positive outlook on the company, which is a reassuring indicator of strong internal sentiment.

Customer Acquisition: Eli Lilly has experienced a considerable uptick in website traffic, reaching an estimated 7.2M visitors. This surge, up by 74% in the last couple of months, suggests growing customer interest and possibly an increased customer base, which is a bullish indicator.

Customer Engagement: The company has seen a significant drop in social media engagement, with 0 followers on Instagram, down by 100%, and 140,000 followers on Twitter, unchanged over the past couple of months. This loss in interest might signal waning public engagement or ineffective social media strategies.

AltIndex AI Score: Eli Lilly and Company received an AI score of 78 from AltIndex, which aggregates multiple data points to predict stock performance. This score is indicative of a buy signal, suggesting that despite some mixed indicators, the stock is considered a good buy based on aggregated data.

Conclusion

In summary, Eli Lilly and Company presents a mixed bag of indicators. While the company demonstrates significant year-over-year growth in revenue, net income, and EBITDA, there are short-term concerns over declining profits and revenue in the latest quarter. The high P/E ratio also raises questions about potential overvaluation. The technical indicators suggest a bullish short-term trend, but the long-term performance shows areas of concern. Alternative data analysis highlights a strong internal sentiment and increased customer acquisition, though social media engagement is lacking.

Given these various factors, a cautious but optimistic recommendation would be to consider buying Eli Lilly and Company's stock. The company's robust year-over-year growth, positive employee outlook, and the bullish short-term trend provide a strong foundation, even though some short-term weaknesses and potential overvaluation are present. Investors should remain vigilant and monitor ongoing performance and market conditions.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.